Medinoah
Latest round
- Series B
Last raised
- Mar 2023
Total raised
- $30M
Investors
- 7
About Medinoah
Established in 2008 and based in Suzhou, China, Medinoah operates as a complex chemical drugs developer that provides drug synthesis, screening and structure optimization, and production process development. In October 2021, Hefei High-tech Zone Management Committee became the strategic partner of the company. In February 2022, the company established Hefei R&D center., Ltd. is the subsidiary of the company. Yanong Wang is the CEO of the company, and he once served as the chief scientist and project leader of Wyeth Corporation of USA. The core research team has master's degree. The company mainly provides services include drug synthesis, screening and structural optimization, process development, analytical development and quality control, and cGMP production. Its products is divided into three series, which include drug impurity standards, chiral intermediates and pharmaceutical intermediates and API. It has many clients, such Celgene, Arvinas, BeBetter Med, etc. The company also provides CRO service, CDMO and CMC services. CRO service includes FTE services, custom synthesis, specialty chemical synthesis and pharmaceutical intermediates library. CDMO and CMC services include API CDMO services, chemical formulation services, CMO pilot and commercial manufacturing services, CMC services and registration support. Its equipment includes nuclear magnetic resonance (NMR), triple quadrupole liquid phase tandem mass spectrometer (LC-MS-MS) and gas chromatography-mass spectrometer (GC-MS).
Who invested in Medinoah
7 investors across 2 rounds
See all investors in Medinoah
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Medinoah
Who invested in Medinoah?
Medinoah has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Medinoah raised?
Medinoah has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Medinoah last raise money?
Medinoah's most recent round on record is a Series B, in Mar 2023.
What does Medinoah do?
Established in 2008 and based in Suzhou, China, Medinoah operates as a complex chemical drugs developer that provides drug synthesis, screening and structure optimization, and production process development.
Where is Medinoah headquartered?
Medinoah is headquartered in Suzhou, China.
Which VCs invest in companies like Medinoah?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Medinoah's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Medinoah? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.